Archive: Company News
Company News: Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for the Treatment of Chronic Heart Failure
— Collaboration with Hannover Medical School (MHH)
Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH). Read more…
Company News: BellaSeno Receives RegMedNet Award for Cultivating Excellence
– Leipzig-based start-up prepares for first clinical trial in 2019
BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technology , today announced it was awarded the 2018 Award for Cultivating Excellence by RegMedNet for its innovation, creativity, professionalism and investment in young professionals. BellaSeno won the public vote after five finalists were shortlisted by an expert jury. The award was established in 2017 to increase the visibility of the most valuable players in regenerative medicine.
Company News: Curetis Announces Financial Results for the First Nine Months of 2018
– Total year-on-year revenue growth of 43% globally, 207% in EMEA direct selling markets
– Initial traction in U.S. market after Unyvero launch
– Strategic collaboration with BCB in Greater China expanded
– Commercial reach expanded to Northern Africa, South America and Asia
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first nine months ended September 30, 2018, and provided a business update for the third quarter of 2018. Read more…
Company News: Curetis Accelerates 510(k) Submission Preparation for Unyvero LRT in BAL Specimen Based on Positive FDA Feedback
— S. FDA and Curetis agree on 510(k) requirements for clearing BAL as additional sample type for Unyvero LRT
— S. commercial roll-out gaining traction, with first dozen Unyvero Analyzers placed and first commercial evaluation agreements signed
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that following a recent meeting, the U.S. FDA has confirmed the suitability of the 510(k) clearance pathway for Curetis’ Unyvero LRT Application Cartridge specifically optimized for the detection of microbial pathogens in bronchoalveolar lavage (“BAL”) samples. Read more…